Argenta Discovery Ltd. Appoints New Chief Financial OfficerKey Appointment Strengthens Management TeamHarlow (UK) 07 October 2002 - Argenta Discovery Limited today announced that Mr Colin Knox has been appointed as Chief Financial Officer. A Chartered Accountant, Colin joins Argenta from his position as Director of Finance, Europe, for a multi-billion dollar, US-listed software company, where he was integral in the expansion of the company's European operations. He also advised on US and UK accounting issues and was seconded to projects within Canada and Brazil. Previously, Colin held the position of business development and strategy consultant with Greenly's Ltd (now Telos Partners), Windsor, UK, and Group Accountant to Life Sciences plc (acquired by US multinational Thermo Electron Corporation), London, UK. Commenting on the appointment, Dr Anthony Baxter, Argenta's CEO, said: "We are delighted that Colin has joined the management team at Argenta. Argenta is a rapidly expanding company that is attracting an increasing number of commercial partners outside the UK and will benefit greatly from Colin's extensive knowledge of European and global finance planning, and many years experience in financial management." Colin is replacing Mr Bruce Powell who has acted as CFO in a part-time position since the company's inception. Argenta is extremely grateful to Bruce for his work in establishing the company's financial management infrastructure and is pleased that Bruce has agreed to stay on the Board as a non-executive Director. Notes to Editors:About Argenta Discovery Ltd Argenta Discovery is an independent discovery company providing peer quality contract services in medicinal chemistry and biochemistry to pharmaceutical companies of all sizes. Argenta draws on its industry experienced scientists to rapidly deliver hit finding capabilities together with the ability to convert and optimize hits and leads into validated, patentable chemical lead series and potential drug candidates. The company has previously worked with or is currently working with Aventis, Pharmagene, Millennium, Adolor, De Novo, GlaxoSmithKline, Lundbeck, Amedis and other undisclosed partners. Argenta also actively works on its own research projects and can source targets via a unique relationship with London's Imperial College School of Medicine (Europe's largest medical school). Patentable lead series resulting from in-house programs will be available for sale or license. Argenta operates in new, state of the art laboratories in Harlow, UK, and is served by nearby London Stansted Airport. The company also has commercial offices in the US and Japan, reflecting its global client base. Its scientific skills include computer-aided drug design, medicinal, parallel and combinatorial chemistry, high throughput analytical chemistry, molecular biology, biochemical assay development, automated molecular and cellular screening and in vitro ADMET screening. For further information please see www.argentadiscovery.com or email info@argentadiscovery.com. For further information, please contact:Argenta Discovery Ltd HCC De Facto Group |
Argenta Discovery 2009 Limited is a company incorporated and registered in England with registered number 06920289 whose registered office and principal place of business is at 8/9 Spire Green Centre, Flex Meadow, Harlow, CM19 5TR, United Kingdom and whose VAT registration number is GB 977 4737 57.